The global response to the COVID-19 pandemic depended on both the ability to read and write the DNA code. DNA reading (sequencing) technologies have developed far beyond those of DNA writing (synthesis) over the last 15 years, meaning we were able to quickly identify and understand the cause of the pandemic, but the equivalent systems for writing DNA still depend on technologies developed over 30 years ago. The result is that designing, building, and testing the new vaccines to fight this and possible future pandemics is too slow. Evonetix fast, highly parallel, gene synthesis platform can reduce the time to prepare DNA ten-fold so we can respond faster and more effectively in the future.
The urgency for development and commercialization of Evonetix’s breakthrough desktop platform is starkly illustrated by the fight against the COVID-19 pandemic. Evonetix’s vital and radically different approach to gene synthesis may play a significant role in the battle against the next pandemic, and the ones after that. The technology holds a great promise for the future, enabling researchers worldwide the ability to develop life-saving drugs and vaccines—quickly, accurately, and cost-effectively.
The Far and Wide Human Impact
DNA synthesis offers the potential for novel strategies for the production of affordable medications and the treatment of disorders and diseases. The opportunities available to synthetic biology are as diverse as pharmaceuticals and drug discovery, advanced biofuels, industrial biotech, specialty chemicals, renewables, agriculture, and materials science. It may help reduce our dependency on petroleum, halt the spread of infectious diseases, and feed the nutritional requirements of a hungry world.
Rapid and accurate gene synthesis accelerates scientists’ ability to use biology on a scale not possible through other means. The technology derived from the collaboration between Evonetix and ADI offers pathways to address humanity's biggest challenges and to create a better, safer, and healthier planet and population.
1Engineering Biology Research Consortium.